During the past decade, University of South Florida- Research Foundation conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "University of South Florida- Research Foundation" are "ESRD" (1 trials), "End Stage Renal Failure on Dialysis" (1 trials), "Hyperplasia" (1 trials) and "Kidney Diseases" (1 trials). Many other conditions were trialed in "University of South Florida- Research Foundation" in a lesser frequency.

Most popular intervention types in "University of South Florida- Research Foundation" are "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Graft, Vascular Wrap" (1 trials), "Lifespan® ePTFE Vascular Graft" (1 trials), "Lifespan® ePTFE Vascular Graft Only" (1 trials) and "Vascular Wrap Paclitaxel-Eluting Mesh" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of South Florida- Research Foundation" are 2 trials for "All" genders.

Currently, there are NaN active trials in "University of South Florida- Research Foundation". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in University of South Florida- Research Foundation, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University of South Florida- Research Foundation, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".